
Inogen INGN
$ 6.63
3.27%
Annual report 2025
added 02-27-2026
Inogen Accounts Receivables 2011-2026 | INGN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Inogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.9 M | 29.6 M | 42.2 M | 62.7 M | 24.5 M | 29.7 M | 34.3 M | 37 M | 31.4 M | 30.8 M | 19.9 M | 19.3 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.7 M | 19.3 M | 33.4 M |
Quarterly Accounts Receivables Inogen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.4 M | 38.6 M | 36.6 M | 29.6 M | 34.2 M | 36 M | 40.2 M | 42.2 M | 48.4 M | 51.1 M | 53.9 M | 62.7 M | 50.5 M | - | 34 M | 24.5 M | 32.9 M | 36.9 M | 38.4 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 37 M | 37 M | 37 M | 37 M | 31.4 M | 31.4 M | 34.8 M | 31.4 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 62.7 M | 10.2 M | 31.7 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Sensus Healthcare
SRTS
|
6.04 M | $ 4.1 | -2.96 % | $ 66.9 M | ||
|
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | ||
|
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
272 M | $ 9.86 | 3.25 % | $ 759 M | ||
|
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | ||
|
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | ||
|
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | ||
|
Delcath Systems
DCTH
|
11.7 M | $ 9.18 | -0.22 % | $ 329 M | ||
|
Stryker Corporation
SYK
|
4.04 B | $ 335.31 | 2.37 % | $ 128 B | ||
|
Dynatronics Corporation
DYNT
|
2.8 M | - | 14.99 % | $ 929 K | ||
|
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | ||
|
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | ||
|
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | ||
|
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | ||
|
TELA Bio
TELA
|
10.3 M | $ 0.71 | 3.13 % | $ 33.3 M | ||
|
CONMED Corporation
CNMD
|
248 M | $ 36.91 | -0.32 % | $ 1.15 B | ||
|
Insulet Corporation
PODD
|
161 M | $ 220.63 | 2.14 % | $ 15.5 B | ||
|
Tandem Diabetes Care
TNDM
|
165 M | $ 23.46 | -3.32 % | $ 1.6 B | ||
|
Electromed
ELMD
|
24.7 M | $ 24.74 | 0.32 % | $ 209 M | ||
|
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.62 | -8.39 % | $ 33.7 M | ||
|
Aethlon Medical
AEMD
|
128 K | $ 2.37 | 2.22 % | $ 3.7 M | ||
|
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | ||
|
LivaNova PLC
LIVN
|
216 M | $ 64.75 | 2.28 % | $ 3.53 B | ||
|
InspireMD
NSPR
|
2.17 M | $ 1.74 | -0.57 % | $ 112 M | ||
|
AdaptHealth Corp.
AHCO
|
371 M | $ 11.6 | 1.84 % | $ 1.57 B | ||
|
Penumbra
PEN
|
190 M | $ 337.13 | 0.26 % | $ 13.1 B | ||
|
MiMedx Group
MDXG
|
75.7 M | $ 4.08 | -0.49 % | $ 603 M | ||
|
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | ||
|
Viemed Healthcare
VMD
|
25.6 M | $ 9.32 | -0.32 % | $ 363 M | ||
|
Myomo
MYO
|
4.1 M | $ 0.69 | -1.61 % | $ 28.9 M | ||
|
NanoVibronix
NAOV
|
98 K | - | - | $ 1.08 M | ||
|
Varex Imaging Corporation
VREX
|
157 M | $ 10.72 | 0.28 % | $ 444 M | ||
|
Vivos Therapeutics
VVOS
|
430 K | $ 1.24 | 7.37 % | $ 6.22 M | ||
|
Inspire Medical Systems
INSP
|
120 M | $ 51.41 | - | $ 1.51 B | ||
|
Pulmonx Corporation
LUNG
|
12.1 M | $ 1.29 | -1.15 % | $ 52.5 M | ||
|
Beyond Air
XAIR
|
710 K | $ 0.74 | 0.01 % | $ 50.1 M | ||
|
Xtant Medical Holdings
XTNT
|
20.7 M | $ 0.57 | 0.85 % | $ 76.2 M |